Alpha Tau Cleared to Complete Glioblastoma Trial After Early 100% Local Disease Control — Alpha Tau Medical Ltd.

Event summary

FDA cleared Alpha Tau to enroll remaining 7 patients in REGAIN trial for recurrent glioblastoma after interim safety review.
Early results from first 3 patients showed 100% local disease control, 67% complete response rate, and manageable adverse events.
Two additional U.S. academic cancer centers approved to join the trial, expanding geographic reach.
Alpha DaRT previously received FDA Breakthrough Device Designation and was accepted into the Total Product Life Cycle Advisory Program.
Approximately 14,000 new glioblastoma cases diagnosed annually in the U.S., with limited treatment options after recurrence.

The big picture

Alpha Tau's progress in the REGAIN trial positions Alpha DaRT as a potential transformative treatment for recurrent glioblastoma, a disease with limited therapeutic options. The FDA's clearance to complete enrollment and the addition of new clinical sites underscore the regulatory and clinical interest in this innovative alpha-radiation therapy. The company's strategic focus on this indication aligns with the broader trend of targeting aggressive cancers with novel radiation technologies.

What we're watching

Trial Momentum: Whether Alpha Tau can sustain the rapid enrollment pace and maintain positive interim results with the remaining patients.
Regulatory Pathway: The pace at which Alpha DaRT advances through the FDA approval process, given its Breakthrough Device Designation and TAP program inclusion.
Commercialization Potential: How the expansion to additional clinical sites will impact the company's ability to gather robust data for potential commercialization.